| Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 117.22 mm | 117.22 mm | 117.22 mm | 117.22 mm | 117.22 mm | 117.22 mm |
| Cash burn (monthly) | 16.57 mm | 6.14 mm | 13.41 mm | 11.76 mm | 13.25 mm | 10.43 mm |
| Cash used (since last report) | 762.18 mm | 282.40 mm | 616.77 mm | 540.91 mm | 609.29 mm | 479.65 mm |
| Cash remaining | -644.97 mm | -165.18 mm | -499.55 mm | -423.70 mm | -492.07 mm | -362.43 mm |
| Runway (months of cash) | -38.9 | -26.9 | -37.3 | -36.0 | -37.1 | -34.8 |
| 13F holders | Current |
|---|---|
| Total holders | 3 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 131.03 mm |
| Total shares | 5.60 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Column Group L P | 2.58 mm | $74.45 mm |
| Venrock Associates V | 1.74 mm | $20.00 mm |
| Bain Capital Life Sciences Fund | 1.27 mm | $36.58 mm |
